医院获得性呼吸道感染患者中的铜绿假单胞菌:欧洲ICU相关呼吸道感染网络的二次分析
该研究为欧洲ICU相关呼吸道感染网络前瞻性队列的二次分析,纳入12个国家2016年5月至2019年8月共1,059例接受微生物检测的医院获得性呼吸道感染患者。铜绿假单胞菌检出率为14.5%(153例),其中5.1%(55例)存在耐药机制,19.6%为多重耐药,11.1%产碳青霉烯酶。呼吸机相关性肺炎占铜绿假单胞菌病例的66%,有与无铜绿假单胞菌感染患者间无显著死亡率差异。风险因素包括COPD GOLD D期、自身免疫病、慢性肾脏病和入ICU第1天AKI。作者认为相当比例患者在接受经验性抗铜绿假单胞菌治疗但并无铜绿假单胞菌感染证据,支持更个体化的经验性治疗。
要点
- 在1,059例ICU医院获得性呼吸道感染患者中,铜绿假单胞菌检出率为14.5%(153例),耐药机制占5.1%(55例)。
- 铜绿假单胞菌分离株中19.6%为多重耐药,11.1%产碳青霉烯酶。
- 铜绿假单胞菌病例中以呼吸机相关性肺炎为主,占66%。
- 有与无铜绿假单胞菌感染患者之间未发现显著死亡率差异。
- 铜绿假单胞菌感染的风险因素包括COPD GOLD D期、自身免疫病、慢性肾脏病和入ICU第1天AKI。
适用人群与场景
- ICU中发生医院获得性呼吸道感染并接受微生物检测的患者,数据来自12个国家的前瞻性队列(2016年5月至2019年8月)。
研究设计与关键结果
- 研究类型为前瞻性队列研究的二次分析,纳入12个国家1,059例接受微生物检测的医院获得性呼吸道感染患者,中位年龄64岁(四分位距49-73岁),男性72%。
- 病原体检出率为67%(710/1,059),主要使用血培养样本(78%)。
- 铜绿假单胞菌检出率为14.5%(153例),耐药机制占5.1%(55例);其中19.6%为多重耐药,11.1%产碳青霉烯酶。
- 铜绿假单胞菌检出率最高的国家为德国、阿根廷和法国。
- 呼吸机相关性肺炎占铜绿假单胞菌病例的66%;脓毒性休克和急性肾损伤是最常见并发症。
- 有与无铜绿假单胞菌感染患者之间未发现显著死亡率差异。
- 风险因素包括COPD GOLD D期、自身免疫病、慢性肾脏病和入ICU第1天AKI。
证据类型、等级与局限
- 证据类型:前瞻性队列研究的二次分析(临床试验注册号NCT03183921)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为铜绿假单胞菌是医院获得性呼吸道感染的主要病原体之一,各国检出率存在差异。
- 作者指出相当比例患者接受经验性抗铜绿假单胞菌治疗但并无铜绿假单胞菌感染证据。
- 作者认为COPD GOLD D期、自身免疫病、慢性肾脏病和AKI是铜绿假单胞菌医院获得性呼吸道感染的关键风险因素,支持更个体化、基于证据的经验性治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nosocomial respiratory infections (NRIs) are the most common complication among patients in the ICU, with Pseudomonas aeruginosa frequently identified. However, the global prevalence of P aeruginosa and associated risk factors remain unclear.
RESEARCH QUESTION: Among patients in the ICU with NRI, what is the international prevalence of P aeruginosa, and which clinical factors are associated with an increased risk?
STUDY DESIGN AND METHODS: This secondary analysis used data from the European Network for ICU-Related Respiratory Infections, a prospective cohort study conducted across 12 countries from May 2016 through August 2019. Data from 1,059 patients with NRI who underwent microbiological testing were analyzed. Descriptive statistics, imputation of missing data, least absolute shrinkage and selection operator regression, elastic net, random forest, and multivariable logistic regression were applied. Model performance was assessed using McFadden's R2 and the Hosmer-Lemeshow test.
RESULTS: The median patient age was 64 years (interquartile range, 49-73 years), and 72% were male. Pathogens were identified in 67% of patients (710 of 1,059), primarily using blood culture samples (78%). P aeruginosa was detected in 14.5% of samples (n = 153), with antimicrobial resistance mechanisms in 5.1% of samples (n = 55). Among these, 19.6% of samples were multidrug resistant and 11.1% of samples produced carbapenemase. The highest prevalence was observed in Germany, Argentina, and France. Ventilator-associated pneumonia was the predominant diagnosis, accounting for 66% of P aeruginosa cases. Septic shock and acute kidney injury (AKI) were the most frequent complications. No significant mortality differences were found between patients with and without P aeruginosa infection. Key risk factors included COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage D, autoimmune disease, chronic kidney disease (CKD), and AKI on day 1.
INTERPRETATION: P aeruginosa is a leading NRI pathogen, with prevalence varying across countries. A high proportion of patients receive empirical anti-Pseudomonas treatment without confirmed infection by P aeruginosa. Key risk factors identified for Pseudomonas NRI were COPD GOLD stage D, autoimmune disease, CKD, and AKI. These findings support the need for more personalized, evidence-based empirical therapy.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03183921; URL: www.
CLINICALTRIALS: gov.
参考来源
- Serrano-Mayorga CC, Olivella-Gomez J, Sanabria-Herrera N, et al. Pseudomonas aeruginosa in Patients With Nosocomial Respiratory Infections: A Secondary Analysis of the European Network for ICU-Related Respiratory Infections. Chest. 2026. PMID: 41520818. doi:10.1016/j.chest.2025.12.033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。